SS Innovations Q1 revenue $5.1M (+40.8% YoY); net loss narrows; FDA submission planned by July 2025

SS Innovations International, Inc.

2025-Q1 EPS reported -$0.03 revenue$5,120,610

Revenue $5.1M (+40.8% YoY); gross margin 21.23% (up 121 bps); net loss $5.7M ($0.03 diluted) vs $9.8M ($0.06) in Q1 2024.
SSi Mantra installations 15 in Q1 (+66.7%), cumulative installed base 78, cumulative surgeries 3,568.
Cash $15.9M, zero long-term debt; subsequently uplisted to Nasdaq on April 25, 2025.
Plan to submit De Novo FDA application for SSi Mantra by July 2025; CE Mark possible late 2025.
Achieved world's first robotic cardiac telesurgery; gained regulatory approvals in Philippines and Ukraine.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.